Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflac-AML Regimen in Pediatric AML
NCT04326439Phase 2Terminated
- Sponsor
- Emory University
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, daunorubicin, Asparaginase, etoposide, gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Emory University. Started Jan 2020; status: terminated.
02
Drugs
cytarabinedaunorubicinAsparaginaseetoposidegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04326439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326439.